Citi Moves to Sidelines Nevro Corp (NVRO), Moves to Neutral, 'uncertainty remains high'

Nevro Corp (NVRO) PT Lowered to $5.50 at Truist Securities

Truist Securities analyst Richard Newitter lowered the price target on Nevro Corp (NYSE: NVRO) to $5.50 (from $10.00) while maintaining a Hold rating.... More

Wolfe Research Upgrades Nevro Corp (NVRO) to Peerperform

Wolfe Research analyst Mike Polark upgraded Nevro Corp (NYSE: NVRO) from Underperform to Peerperform.

The analyst comments: "In 2025 and beyond, modeling posture calls for ~3% total company growth, leaving our estimates below Street. This 3% input aligns with 2018-2024E average annual real... More

Nevro Corp (NVRO) PT Lowered to $8 at Baird

Baird analyst David Rescott lowered the price target on Nevro Corp (NYSE: NVRO) to $8.00 (from $11.00) while maintaining a Neutral rating.... More

Nevro Corp (NVRO) PT Lowered to $7 at Jefferies

Jefferies analyst Matthew Taylor lowered the price target on Nevro Corp (NYSE: NVRO) to $7.00 (from $10.00) while maintaining a Underperform rating.

The analyst comments "NVRO reported 2Q revs of $104 MM (+4.2% xfx), vs cons $107 MM. EBITDA was $3 MM vs cons -$3 MM. NVRO... More

Nevro Corp (NVRO) PT Lowered to $7 at Piper Sandler

Piper Sandler analyst Adam Maeder lowered the price target on Nevro Corp (NYSE: NVRO) to $7.00 (from $12.00) while maintaining a Underweight rating.

The analyst commented, "Nevro announced Q2 results that included revenue of $104.2M, which came in below consensus ($107.1M), while adj. EBITDA was relatively... More

Nevro Corp (NVRO) PT Lowered to $7 at RBC Capital

RBC Capital analyst Shagun Singh lowered the price target on Nevro Corp (NYSE: NVRO) to $7.00 (from $16.00) while maintaining a Sector Perform rating.

The analyst comments "NVRO delivered a Q2'24 miss on sales while EPS beat, and FY24 revenue guidance... More

Nevro Corp (NVRO) PT Lowered to $8 at Canaccord Genuity

(Updated - August 7, 2024 6:58 AM EDT)

Canaccord Genuity analyst William Plovanic lowered the price target on Nevro Corp (NYSE: NVRO) to $8.00 (from $11.00) while maintaining a Hold rating.

The analyst commented: "Nevro reported a Q2 miss and reduced its FY24 outlook. Q2 revenue of $104.2M (-4.3% Y/Y, -4.2% Y/Y CC) missed our... More

Nevro Corp (NVRO) PT Lowered to $9 at Mizuho

Mizuho analyst Anthony Petrone lowered the price target on Nevro Corp (NYSE: NVRO) to $9.00 (from $16.00) while maintaining a Neutral rating.... More

Wells Fargo Downgrades Nevro Corp (NVRO) to Underweight

(Updated - August 7, 2024 8:14 AM EDT)

Wells Fargo analyst Nathan Treybeck downgraded Nevro Corp (NYSE: NVRO) from Equal Weight to Underweight with a price target of $5.50.

The analyst comments "NVRO announced a strategic review. Given the market dynamics, NVRO's Board and mgmt retained advisors and over the next... More

JMP Securities Downgrades Nevro Corp (NVRO) to Market Perform

JMP Securities analyst David Turkaly downgraded Nevro Corp (NYSE: NVRO) from Market Outperform to Market Perform.

The analyst comments: "We are downgrading our rating on shares of Nevro Corp. to Market Perform from Market Outperform following the release of 2Q24 results. All in, sales came... More

JPMorgan Downgrades Nevro Corp (NVRO) to Underweight

JPMorgan analyst Robert Marcus downgraded Nevro Corp (NYSE: NVRO) from Neutral to Underweight.

The analyst comments: "While Nevro has taken steps to shore up growth and diversify the business via PDN and with the recent acquisition of Vyrsa in SI Joint,... More

Nevro (NVRO) Tops Q2 EPS by 17c, provides guidance

Nevro (NYSE: NVRO) reported Q2 EPS of ($0.53), $0.17 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $104.16 million versus the consensus estimate of $107.11 million.

GUIDANCE:

Nevro sees FY2024 revenue of $400-405 million, versus the consensus of $439.9... More